abiraterone,olaparib
astrazeneca,merck
['#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'propel']
noel clarke presenting propel os data #gu23 improvement in os of 7 months in itt population largely driven by hrrm pts need longer-term fu to see where os lands in hrrm vs non-hrr 
GU Med Onc, A/Prof Peter Mac/UoM, ANZUP Translational Chair, #UpfrontPSMA Alliance, COSA Urologic Oncology Chair, NHMRC L1 Investigator. Opinions my own.